Form 4: Mirum Pharmaceuticals Director Lon Cardon Acquires Stock Options and Restricted Stock Units

Director Lon Cardon reports acquisition of stock options and restricted stock units in Mirum Pharmaceuticals.

Summary

• On June 5, 2024, Lon Cardon, a director at Mirum Pharmaceuticals, acquired 8,779 stock options with an exercise price of $26.30.
• These options vest on the first anniversary of the grant date but will be fully vested by the date of the company's 2025 annual stockholder meeting.
• Cardon also acquired 5,703 restricted stock units (RSUs), each representing a contingent right to receive one share of Mirum Pharmaceuticals' common stock.
• These RSUs also vest on the first anniversary of the grant date and will be fully vested by the date of the company's 2025 annual stockholder meeting.
• Following these transactions, Cardon directly owns 8,779 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock options and RSU grants to a director, indicating standard compensation practices.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedules for both the stock options and RSUs are tied to the company's 2025 annual stockholder meeting, suggesting a focus on long-term performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options and RSUs by a director can positively influence shareholder sentiment, reflecting confidence in the company's prospects.

Key Dates